TY - JOUR
T1 - TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth
AU - Inoki, Ken
AU - Ouyang, Hongjiao
AU - Zhu, Tianqing
AU - Lindvall, Charlotta
AU - Wang, Yian
AU - Zhang, Xiaojie
AU - Yang, Qian
AU - Bennett, Christina
AU - Harada, Yuko
AU - Stankunas, Kryn
AU - Wang, Cun yu
AU - He, Xi
AU - MacDougald, Ormond A.
AU - You, Ming
AU - Williams, Bart O.
AU - Guan, Kun Liang
N1 - Funding Information:
We thank Drs. Eric Fearon, Yue Xiong, and Martha Somerman for providing reagents and cells and Cassandra Zylstra for technical assistance. We also thank Huira Chong, Michael N. Corradetti, and Chung-Han Lee for critical reading of the manuscript. This work is supported by grants from NIH (K.-L.G, H.O, and C.-Y.W.), American Association of Endodontics (H.O.), and Michigan Cancer Center and Diabetic Center (K.-L.G).
PY - 2006/9/8
Y1 - 2006/9/8
N2 - Mutation in the TSC2 tumor suppressor causes tuberous sclerosis complex, a disease characterized by hamartoma formation in multiple tissues. TSC2 inhibits cell growth by acting as a GTPase-activating protein toward Rheb, thereby inhibiting mTOR, a central controller of cell growth. Here, we show that Wnt activates mTOR via inhibiting GSK3 without involving β-catenin-dependent transcription. GSK3 inhibits the mTOR pathway by phosphorylating TSC2 in a manner dependent on AMPK-priming phosphorylation. Inhibition of mTOR by rapamycin blocks Wnt-induced cell growth and tumor development, suggesting a potential therapeutic value of rapamycin for cancers with activated Wnt signaling. Our results show that, in addition to transcriptional activation, Wnt stimulates translation and cell growth by activating the TSC-mTOR pathway. Furthermore, the sequential phosphorylation of TSC2 by AMPK and GSK3 reveals a molecular mechanism of signal integration in cell growth regulation.
AB - Mutation in the TSC2 tumor suppressor causes tuberous sclerosis complex, a disease characterized by hamartoma formation in multiple tissues. TSC2 inhibits cell growth by acting as a GTPase-activating protein toward Rheb, thereby inhibiting mTOR, a central controller of cell growth. Here, we show that Wnt activates mTOR via inhibiting GSK3 without involving β-catenin-dependent transcription. GSK3 inhibits the mTOR pathway by phosphorylating TSC2 in a manner dependent on AMPK-priming phosphorylation. Inhibition of mTOR by rapamycin blocks Wnt-induced cell growth and tumor development, suggesting a potential therapeutic value of rapamycin for cancers with activated Wnt signaling. Our results show that, in addition to transcriptional activation, Wnt stimulates translation and cell growth by activating the TSC-mTOR pathway. Furthermore, the sequential phosphorylation of TSC2 by AMPK and GSK3 reveals a molecular mechanism of signal integration in cell growth regulation.
UR - http://www.scopus.com/inward/record.url?scp=33748153690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748153690&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2006.06.055
DO - 10.1016/j.cell.2006.06.055
M3 - Article
C2 - 16959574
AN - SCOPUS:33748153690
VL - 126
SP - 955
EP - 968
JO - Cell
JF - Cell
SN - 0092-8674
IS - 5
ER -